Menu Search
Equities

Galmed Pharmaceuticals Ltd

GPH:FRA

Galmed Pharmaceuticals Ltd

Actions
  • Price (EUR)0.228
  • Today's Change-2.51 / -91.67%
  • Shares traded1.93k
  • 1 Year change-94.89%
  • Beta--
Data delayed at least 15 minutes, as of Aug 29 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

  • Revenue in USD (TTM)0.00
  • Net income in USD-5.88m
  • Incorporated2013
  • Employees3.00
  • Location
    Galmed Pharmaceuticals Ltd16 Tiomkin StreetTEL AVIV-YAFO 6578317IsraelISR
  • Phone+972 36938448
  • Fax+972 36938447
  • Websitehttps://www.galmedpharma.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.